Apnea Risk Evaluation System (ARES™):

The Apnea Risk Evaluation System (ARES) integrates physiological data acquired in-home with clinical history and anthropomorphic data to determine presence and severity of Obstructive Sleep Apnea (OSA). The ARES has been cleared for use by the United States Food and Drug Administration (FDA), ISO 13485 certified for Europe and Canada.

The ARES integrates:

ARES Unicorder: a sleep-wearable, wireless physiological recorder worn on the forehead that acquires and stores up to 4 nights of nocturnal data. The ARES Unicorder measures blood oxygen saturation (SpO2) and pulse rate (reflectance pulse oximetry), airflow (by nasal cannula connected to a pressure transducer), respiratory effort (a combined signal using pressure transducer sensing forehead venous pressure, venous volume by photoplethysmography, and actigraphy), snoring levels (calibrated acoustic microphone), head movement and head position (accelerometers). When worn in the home, the ARES provides a better profile of the patient's breathing during sleep in his/her normal environment. Audio and visual indicators notify the user when the Unicorder requires adjustment, thus increasing reliability of the ARES in the home. The small size of the Unicorder allows it to be comfortably worn in all sleep positions.

ARES Screener: a validated predictor of OSA risk (those in need of a sleep study based on a predicted apnea/hypopnea index > 5 events/hour) and OSA severity (i.e., minimal, mild, moderate or severe) using responses to questions about body type, symptoms of daytime drowsiness, snoring, and other sleep-related characteristics or health conditions associated with OSA. The results can be used to rapidly screen large populations to determine a prior probability of obstructive sleep apnea (OSA). The results are also used to supplement the physiological data obtained in the ARES Sleep Apnea Study.

ARES Software: provides an integrated approach for data management and study processing. ARES Insight's patented algorithms recognize changes in SpO2, pulse rate, head movement, snoring level, and airflow that result from abnormal breathing during sleep. The full disclosure recordings can be manually inspected and the automated results can be edited by a physician. Automated and edited events (ARES-RDI), positional influence on the ARES-RDI, hypoxemia statistics, and ARES questionnaire results are calculated. This information and any evidence suggestive of sleep disorders other than OSA are summarized in a concise two-page report.